Nuron Biotech acquires a vaccine from Pfizer

Posted: December 11, 2012

Nuron Biotech Inc., a specialty biologies and vaccines company based in Exton, said it acquired from Pfizer Inc., the vaccine Meningitec, used for the prevention of a potentially deadly infection caused by Neisseria meningitidis serogroup C.

There are an estimated 500,000 cases of the infection annually worldwide, according to Nuron Biotech, but the U.S. Centers for Disease Control and Prevention estimated the rate of infection in the U.S. is 0.5 per 100,000 people.

Meningitec is a preservative-free vaccine, which is registered in 23 countries.

Neisseria meningitidis can lead to meningitis, sepsis and pneumonia. Without treatment, the mortality rate can reach 90 percent, and death may result within 24 to 48 hours.    - David Sell

|
|
|
|
|